[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endogenous-cushing-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endogenous-cushing-syndrome":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100549170","a-block-and-replace-therapy-with-osilodrostat-and-concomitant-glucocorticoid-replacement-100549170",false,"NCT06430528","A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement","Inclusion Criteria:\n\n* Endogenous Cushing syndrome, either following surgery or not candidates for surgery\n* Under consideration to receive osilodrostat as part of their clinical care\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Treatment with other investigational drugs within 30 days or five half-lives (whichever is longer).\n* A history of hypersensitivity to osilodrostat or therapies of a similar chemical class.","ALL","18 Years","75 Years",{"count":19,"type":20},12,"ESTIMATED","OBSERVATIONAL","The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace approach).\n\nThe investigators are also evaluating new biomarker steroids to reflect adequate osilodrostat dosing, the durability and safety, and clinical improvement during treatment.",[24,25,26],"Endogenous Cushing Syndrome","Adrenal Insufficiency","Hypercortisolism",[28,29,30,31],"Osilodrostat","Glucocorticoid","Methylprednisolone","Medrol","RECRUITING","2025-08-14",{"date":35,"type":36},"2025-08-20","ACTUAL",{"date":38,"type":36},"2024-07-19",{"date":40,"type":20},"2027-08",{"name":42,"class":43},"University of Michigan","OTHER"]